Simultaneous chylous ascites and chylothorax during ramucirumab plus docetaxel chemotherapy in a patient with non-small lung cell cancer

被引:0
作者
Makoto Arai
Susumu Maruta
Meng Meng Fan
Chiaki Imai
Akinobu Tawada
Yuichi Takiguchi
机构
[1] Chiba University,Department of Medical Oncology, Graduate School of Medicine
[2] Chiba University Hospital,Division of Pharmacy
来源
International Cancer Conference Journal | 2019年 / 8卷
关键词
Ramucirumab; Docetaxel; Chylous ascites; Chylothorax;
D O I
暂无
中图分类号
学科分类号
摘要
A 69-year-old woman was diagnosed as having non-small cell lung cancer (adenocarcinoma, T1aN3M1b). She had no history of surgery or abdominal trauma. She was treated with ramucirumab (10 mg/kg) plus docetaxel (60 mg/m2) intravenously (RAM + DTX) every 3 weeks. Although an enhanced CT examination showed a partial tumor response after eight courses of RAM + DTX, she gradually began to experience abdominal fullness with severe peripheral pitching edema. Her body weight increased by 18 kg in 2 months and RAM + DTX chemotherapy was discontinued. An enhanced CT examination showed a large amount of ascites and pleural effusion, with no obstructions of the central vein or lymphatic ducts. The ascites were white and milky in appearance and contained 527 mg/dL of triglyceride. In addition, her pleural effusion was also white and milky in appearance. No further increases in ascites and pleural effusion were observed thereafter. Four months after her last RAM + DTX chemotherapy, she continued to exhibit a partial response and no increases in ascites or pleural effusion were present. The chylous effusion might have been caused by the RAM + DTX chemotherapy.
引用
收藏
页码:114 / 117
页数:3
相关论文
共 23 条
[1]  
Arnold D(2017)Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab Ann Oncol 28 2932-2942
[2]  
Fuchs CS(2010)Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2 J Clin Oncol 28 780-787
[3]  
Tabernero J(2017)Review article: the diagnostic approach and current management of chylous ascites Aliment Pharmacol Ther 46 816-824
[4]  
Spratlin J(2013)Vascular endothelial growth factor receptor-2 promotes the development of the lymphatic vasculature PLoS One 8 e74686-108
[5]  
Cohen R(2007)Elevated expression of VEGFR-3 in lymphatic endothelial cells from lymphangiomas BMC Cancer 7 105-undefined
[6]  
Eadens M(2015)Simultaneous chylothorax and chylous ascites in a patient with castration-resistant prostate cancer after docetaxel chemotherapy: an unusual manifestation Int J Urol 22 614-undefined
[7]  
Lizaola B(2018)Surgical treatment following chemo-targeted therapy with bevacizumab for lung metastasis from colorectal carcinoma: analysis of safety and histological therapeutic effects in patients treated at a single institution Case Rep Oncol 11 98-undefined
[8]  
Bonder A(undefined)undefined undefined undefined undefined-undefined
[9]  
Trivedi HD(undefined)undefined undefined undefined undefined-undefined
[10]  
Dellinger MT(undefined)undefined undefined undefined undefined-undefined